Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-04
DOI
10.3389/fcell.2021.668131
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis
- (2021) Yu-ting Liu et al. ACTA PHARMACOLOGICA SINICA
- Milestones in Personalized Medicine in Pemphigus and Pemphigoid
- (2021) Katja Bieber et al. Frontiers in Immunology
- Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
- (2021) Philipp von Hundelshausen et al. Cancers
- Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
- (2021) H. Yesid Estupiñán et al. Frontiers in Cell and Developmental Biology
- Bruton’s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells
- (2020) Ahmed Nadeem et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2020) Daniela Angst et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN‐473) in the treatment of canine pemphigus foliaceus
- (2020) Elizabeth C. Goodale et al. VETERINARY DERMATOLOGY
- The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
- (2020) Steven P. Treon et al. BLOOD
- Protective Role of BTK Inhibitors in Patients with Chronic Lymphocytic Leukemia and COVID‐19
- (2020) Santiago Thibaud et al. BRITISH JOURNAL OF HAEMATOLOGY
- A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
- (2020) Isabella Quinti et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover
- (2020) Annarosa Soresina et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study)
- (2020) Stanley Cohen et al. Arthritis & Rheumatology
- Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
- (2020) Sebastian Torke et al. ACTA NEUROPATHOLOGICA
- Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience
- (2020) Anthony R. Mato et al. BLOOD
- Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells
- (2020) Naif O. Al-Harbi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis
- (2020) Melanie C. Dispenza et al. JOURNAL OF CLINICAL INVESTIGATION
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
- (2020) Lydia Scarfò et al. LEUKEMIA
- Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
- (2020) Mark Roschewski et al. Science Immunology
- Open trial of Bruton’s tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus
- (2020) Elizabeth C. Goodale et al. VETERINARY DERMATOLOGY
- Atypical course of COVID-19 in patient with Bruton agammaglobulinemia
- (2020) Ivana Milošević et al. Journal of Infection in Developing Countries
- Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
- (2019) Alexander P. de Porto et al. MOLECULAR MEDICINE
- Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
- (2019) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
- (2019) Philipp Haselmayer et al. JOURNAL OF IMMUNOLOGY
- Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
- (2019) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus
- (2019) Damien Blez et al. HAEMATOLOGICA
- Evidence for enhanced Bruton’s tyrosine kinase activity in transitional and naïve B cells of patients with granulomatosis with polyangiitis
- (2019) Anouk von Borstel et al. RHEUMATOLOGY
- Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
- (2019) Richard D. Caldwell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- (2019) Bo Sun et al. ChemMedChem
- Inhibition of Bruton’s tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy
- (2019) Ahmed Nadeem et al. PHARMACOLOGICAL RESEARCH
- Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment
- (2019) Alessandro Prezzo et al. LEUKEMIA RESEARCH
- Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury
- (2018) Jon M. Florence et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque–triggered thrombus formation in humans
- (2018) Kristina Busygina et al. BLOOD
- The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity
- (2018) Jasper Rip et al. CRITICAL REVIEWS IN IMMUNOLOGY
- Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation
- (2018) Yangyang Gu et al. INFLAMMATION
- Disrupting the Btk Pathway Suppresses COPD-Like Lung Alterations in Atherosclerosis Prone ApoE−/− Mice Following Regular Exposure to Cigarette Smoke
- (2018) Jon Florence et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of Bruton’s tyrosine kinase in B cells and malignancies
- (2018) Simar Pal Singh et al. Molecular Cancer
- BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance
- (2018) Takashi Matsushita et al. Science Advances
- Integrated B Cell, Toll-like, and BAFF Receptor Signals Promote Autoantibody Production by Transitional B Cells
- (2018) Samuel W. Du et al. JOURNAL OF IMMUNOLOGY
- BAFF and BAFF-Receptor in B Cell Selection and Survival
- (2018) Cristian R. Smulski et al. Frontiers in Immunology
- The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation
- (2017) Nicole Stadler et al. HAEMATOLOGICA
- Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase
- (2017) Xiao Liu et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- TLR4 signals in B lymphocytes are transduced via the B cell antigen receptor and SYK
- (2017) Edina Schweighoffer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
- (2017) Kathleen M. Gillooly et al. PLoS One
- The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation
- (2017) Nicole Stadler et al. HAEMATOLOGICA
- Brief Report: Defective Early B Cell Tolerance Checkpoints in Sjögren's Syndrome Patients
- (2017) Salomé Glauzy et al. Arthritis & Rheumatology
- Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease
- (2017) Odilia B. J. Corneth et al. Arthritis & Rheumatology
- Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
- (2017) Alexander N. R. Weber et al. Frontiers in Immunology
- BAFF upregulates CD28/B7 and CD40/CD154 expression and promotes mouse T and B cell interaction in vitro via BAFF receptor
- (2016) Feng Zhang et al. ACTA PHARMACOLOGICA SINICA
- Systemic sclerosis: New evidence re-enforces the role of B cells
- (2016) Lazaros I. Sakkas et al. AUTOIMMUNITY REVIEWS
- Central role for marginal zone B cells in an animal model of Sjogren's syndrome
- (2016) Long Shen et al. CLINICAL IMMUNOLOGY
- B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence
- (2016) Silke Kinzel et al. CNS DRUGS
- The Neutrophil Btk Signalosome Regulates Integrin Activation during Sterile Inflammation
- (2016) Stephanie Volmering et al. IMMUNITY
- Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma
- (2016) Jonathan E. Phillips et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome
- (2016) Divi Cornec et al. JOURNAL OF AUTOIMMUNITY
- Enhanced Expression of Bruton’s Tyrosine Kinase in B Cells Drives Systemic Autoimmunity by Disrupting T Cell Homeostasis
- (2016) Odilia B. J. Corneth et al. JOURNAL OF IMMUNOLOGY
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
- (2016) Stefania Fiorcari et al. Oncotarget
- Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis
- (2016) Lindsay E. Nyhoff et al. Arthritis & Rheumatology
- Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy
- (2015) M. F. M. de Rooij et al. BLOOD
- Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function
- (2015) Li Ren et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice
- (2015) Steven D. Schutt et al. PLoS One
- Amplification of IL-21 signalling pathway through Bruton’s tyrosine kinase in human B cell activation
- (2015) Sheau-Pey Wang et al. RHEUMATOLOGY
- Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury
- (2015) Minako Ito et al. Nature Communications
- Bruton’s Tyrosine Kinase Phosphorylates DDX41 and Activates Its Binding of dsDNA and STING to Initiate Type 1 Interferon Response
- (2015) Koon-Guan Lee et al. Cell Reports
- Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
- (2015) Gayathri Natarajan et al. OncoImmunology
- Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma
- (2015) Laura Soucek et al. NEOPLASIA
- Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury
- (2014) Agnieszka Krupa et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants
- (2014) Linda M Hartkamp et al. ANNALS OF THE RHEUMATIC DISEASES
- Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
- (2014) Jason A. Dubovsky et al. JOURNAL OF CLINICAL INVESTIGATION
- Essential Roles for the Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate Macrophage Survival
- (2014) M. Melcher et al. JOURNAL OF IMMUNOLOGY
- Bruton's Tyrosine Kinase Promotes Persistence of Mature Anti-Insulin B Cells
- (2014) R. H. Bonami et al. JOURNAL OF IMMUNOLOGY
- CD4+T Cells and CD40 Participate in Selection and Homeostasis of Peripheral B Cells
- (2014) Marc A. Schwartz et al. JOURNAL OF IMMUNOLOGY
- Btk Regulates Macrophage Polarization in Response to Lipopolysaccharide
- (2014) Joan Ní Gabhann et al. PLoS One
- Bruton's Tyrosine Kinase and Protein Kinase C µ Are Required for TLR7/9-Induced IKKα and IRF-1 Activation and Interferon-β Production in Conventional Dendritic Cells
- (2014) Yan-Feng Li et al. PLoS One
- Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells
- (2013) Jingming Wang et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The BAFF Receptor Transduces Survival Signals by Co-opting the B Cell Receptor Signaling Pathway
- (2013) Edina Schweighoffer et al. IMMUNITY
- Bruton’s Tyrosine Kinase Mediates the Synergistic Signalling between TLR9 and the B Cell Receptor by Regulating Calcium and Calmodulin
- (2013) Elaine F. Kenny et al. PLoS One
- Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF
- (2013) E. Y. Abu-Rish et al. RHEUMATOLOGY
- Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy
- (2012) Nishath Hamza et al. ANNALS OF THE RHEUMATIC DISEASES
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice
- (2012) L. P. Kil et al. BLOOD
- Btk is a positive regulator in the TREM-1/DAP12 signaling pathway
- (2011) T. Ormsby et al. BLOOD
- Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor
- (2011) Donald MacGlashan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Absence of Tec Family Kinases Interleukin-2 Inducible T cell Kinase (Itk) and Bruton's Tyrosine Kinase (Btk) Severely Impairs FcϵRI-dependent Mast Cell Responses
- (2011) Archana S. Iyer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
- (2011) Betty Y Chang et al. ARTHRITIS RESEARCH & THERAPY
- E-selectin engages PSGL-1 and CD44 through a common signaling pathway to induce integrin L 2-mediated slow leukocyte rolling
- (2010) T. Yago et al. BLOOD
- Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia
- (2010) K. Fiedler et al. BLOOD
- Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) 2 and PI3K pathways
- (2010) H. Mueller et al. BLOOD
- Genes on the X chromosome affect development of collagen-induced arthritis in mice
- (2010) L. JANSSON et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Therapeutic Targeting of Syk in Autoimmune Diabetes
- (2010) L. Colonna et al. JOURNAL OF IMMUNOLOGY
- Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
- (2010) Julie A Di Paolo et al. Nature Chemical Biology
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians
- (2009) B. Rueda et al. ANNALS OF THE RHEUMATIC DISEASES
- BANK1is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects withIRF5andSTAT4
- (2009) P. Dieudé et al. ARTHRITIS AND RHEUMATISM
- Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations
- (2009) Pravitt Gourh et al. JOURNAL OF AUTOIMMUNITY
- B Cell Receptor-Mediated Sustained c-Rel Activation Facilitates Late Transitional B Cell Survival through Control of B Cell Activating Factor Receptor and NF- B2
- (2009) I. Castro et al. JOURNAL OF IMMUNOLOGY
- Reduced Diabetes in btk-Deficient Nonobese Diabetic Mice and Restoration of Diabetes with Provision of an Anti-Insulin IgH Chain Transgene
- (2009) P. L. Kendall et al. JOURNAL OF IMMUNOLOGY
- The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils
- (2008) M. Kneidinger et al. BLOOD
- Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF- B
- (2008) L. Yu et al. BLOOD
- Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals
- (2008) Masahiro Shinohara et al. CELL
- The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast Maturation
- (2008) Seoung Hoon Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bruton's Tyrosine Kinase Separately Regulates NFκB p65RelA Activation and Cytokine Interleukin (IL)-10/IL-12 Production in TLR9-stimulated B Cells
- (2008) Koon-Guan Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- B-Cell Infiltrates Induce Endosteal Bone Formation in Inflammatory Arthritis
- (2008) Silvia Hayer et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells
- (2008) Kristina E. Halcomb et al. MOLECULAR IMMUNOLOGY
- Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling
- (2008) Jason E Stadanlick et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search